Krystal Biotech Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Krystal Biotech yıllık ortalama 58.8% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 30% annual. Gelirler growing yılda ortalama 77.8% oranında artmaktadır. Krystal Biotech'in özkaynak karlılığı 16.8% ve net marjı 52.6%'dir.
Anahtar bilgiler
58.84%
Kazanç büyüme oranı
58.39%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.04% |
| Gelir büyüme oranı | 77.85% |
| Özkaynak getirisi | 16.80% |
| Net Marj | 52.64% |
| Sonraki Kazanç Güncellemesi | 04 May 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
KRYS: Oncology Immunotherapy RMAT And Respiratory Programs Will Test Rare Disease Optimism
Analysts have lifted their average price target on Krystal Biotech by $7, reflecting updates to models around Vyjuvek sales expectations, FY25 financials, and the advancing pipeline, while incorporating a slightly higher discount rate and modestly revised revenue growth, profit margin, and P/E assumptions. Analyst Commentary Recent Street research on Krystal Biotech shows a wide spread of opinion, with several firms lifting price targets following the latest quarterly report and updated models for Vyjuvek and the broader pipeline.
KRYS: Future CF And Ophthalmology Readouts Will Drive Long Term Upside
Krystal Biotech's analyst price target is maintained at $371, with analysts pointing to refined revenue growth and margin assumptions, along with Q4-driven updates to Vyjuvek forecasts and the broader pipeline, as key supports for the current valuation framework. Analyst Commentary Bullish analysts have been steadily revisiting their models on Krystal Biotech following recent updates on Vyjuvek, the broader pipeline, and Q4 results.KRYS: Future CF And Ophthalmology Readouts Will Shape Long Term Upside
Narrative Update on Krystal Biotech The analyst fair value estimate for Krystal Biotech has shifted from $336 to $371, with the change largely tied to higher Vyjuvek sales assumptions, updated FY25 forecasts, and continued progress across multiple registrational and pivotal pipeline programs cited in recent research updates. Analyst Commentary Recent research updates on Krystal Biotech point to a cluster of upward price target revisions, with bullish analysts citing refreshed financial models, Vyjuvek launch assumptions, and advancing clinical programs across multiple indications as key inputs.KRYS: Rising Oncology And Respiratory Pipeline Expectations May Test Rare Disease Optimism
The analyst price target for Krystal Biotech has been raised from $202 to $241, with analysts pointing to updated models that reflect higher Vyjuvek sales assumptions, refined FY25 financials, and advancing registrational trials across multiple programs. Analyst Commentary Recent Street research on Krystal Biotech highlights a series of upward price target revisions clustered around the latest quarterly update, Vyjuvek launch assumptions, and progress across the pipeline.
KRYS: Future Returns Will Reflect Vyjuvek Penetration And CF And Oncology Pipeline Execution
Narrative Update: Krystal Biotech Analyst Price Target Shift The analyst price target for Krystal Biotech has been revised higher from $273.60 to $291.22, with analysts pointing to recent model updates that reflect Vyjuvek demand trends, advancing ophthalmology programs, and early data from the broader pipeline. Analyst Commentary Recent Street research on Krystal Biotech points to a cluster of upward price target revisions, with most commentary tying those changes to product traction for Vyjuvek, the maturing ophthalmology pipeline, and early data in cystic fibrosis and other programs.
The Rare Disease Rocket Ship
Krystal Biotech reports tomorrow, February 17, 2026. The narrative is no longer about survival; it’s about dominance.Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update
Feb 10KRYS: Future CF Data Readouts May Redefine Long Term Upside Potential
Analysts have increased their price target on Krystal Biotech from $252 to $336, citing updated models that factor in revised assumptions for revenue growth, profit margins, and future P/E multiples following recent clinical data and pipeline updates. Analyst Commentary Recent Street research on Krystal Biotech has centered on a series of higher price targets, with bullish analysts revisiting their models after clinical updates and product pipeline progress.KRYS: Future Returns Will Reflect 96% Margins And Early CF Pipeline Progress
We are raising our analyst price target on Krystal Biotech from $223 to $273.60. This reflects updated models that incorporate recent analyst work on Vyjuvek, early KB407 cystic fibrosis data, and revised assumptions for revenue growth, profit margin, and future P/E multiples.KRYS: Elevated Expectations For Rare Disease Portfolio May Prove Unsustainable
Analysts have lifted their Krystal Biotech fair value estimate from US$176 to US$202, citing higher price targets from recent research, improving access to capital for biotech, and support from Vyjuvek revenue trends and gross margin performance. Analyst Commentary Recent Street research has generally framed Krystal Biotech within a more constructive backdrop for U.S. biotech, pointing to supportive data readouts, active dealmaking by larger peers, and what some describe as better access to capital.KRYS: Future Returns Will Reflect 96% Margins And Expanding International Uptake
Analysts have nudged their price target on Krystal Biotech higher to about $220, reflecting stronger than expected Vyjuvek revenue, early traction from the Germany launch, and exceptionally high gross margins that support the company’s long term profitability outlook. Analyst Commentary Bullish analysts point to the latest quarter as evidence that Krystal Biotech is executing ahead of expectations, with Vyjuvek demand and geographic expansion translating into faster top line growth and stronger earnings power than previously modeled.KRYS: Future Results Will Reflect Margin Strength and International Launch Performance
Analysts have raised their price target for Krystal Biotech to $220, up from $216. They cite stronger-than-expected Vyjuvek revenue, international sales growth, and robust gross margins as key drivers behind the increased valuation.KRYS: Future Momentum Will Depend on Gross Margin Strength and Pipeline Progress
Analysts have increased Krystal Biotech’s price target from $212.50 to $223.00. They cite stronger-than-expected Vyjuvek revenue, expansion in Germany, and improved profit margins as key factors supporting the higher valuation.Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings
Nov 10
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Krystal Biotech's average analyst price target has been revised downward, with a reduction of up to $10 per share. Analysts cite updated product prioritizations, mixed quarterly results, and cautious near-term revenue forecasts.Global Expansion And Clinical Readouts Will Unlock New Markets
The analyst consensus price target for Krystal Biotech has increased from $205.20 to $212.50. This change reflects updated evaluations as analysts factor in new product development priorities and ongoing commercial performance.Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher
Oct 09Why We're Not Concerned Yet About Krystal Biotech, Inc.'s (NASDAQ:KRYS) 26% Share Price Plunge
May 23Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Feb 21Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14
Expanding Global Reach With VYJUVEK Set To Skyrocket Revenue And Sharpen Market Edge
International expansion and upcoming product launches indicate significant potential for revenue growth and market diversification.Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Krystal Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 25 | 389 | 205 | 147 | 58 |
| 30 Sep 25 | 373 | 199 | 137 | 57 |
| 30 Jun 25 | 359 | 147 | 128 | 56 |
| 31 Mar 25 | 333 | 124 | 120 | 57 |
| 31 Dec 24 | 291 | 89 | 114 | 54 |
| 30 Sep 24 | 242 | 52 | 107 | 51 |
| 30 Jun 24 | 166 | 106 | 102 | 49 |
| 31 Mar 24 | 96 | 57 | 100 | 45 |
| 31 Dec 23 | 51 | 11 | 98 | 46 |
| 30 Sep 23 | 9 | -30 | 98 | 46 |
| 30 Jun 23 | 0 | -140 | 94 | 47 |
| 31 Mar 23 | 0 | -135 | 86 | 45 |
| 31 Dec 22 | 0 | -140 | 79 | 42 |
| 30 Sep 22 | 0 | -130 | 69 | 41 |
| 30 Jun 22 | 0 | -115 | 59 | 35 |
| 31 Mar 22 | 0 | -104 | 51 | 31 |
| 31 Dec 21 | 0 | -70 | 42 | 28 |
| 30 Sep 21 | 0 | -58 | 32 | 25 |
| 30 Jun 21 | 0 | -52 | 27 | 24 |
| 31 Mar 21 | 0 | -43 | 21 | 21 |
| 31 Dec 20 | 0 | -32 | 15 | 18 |
| 30 Sep 20 | 0 | -27 | 12 | 17 |
| 30 Jun 20 | 0 | -22 | 9 | 15 |
| 31 Mar 20 | 0 | -20 | 7 | 16 |
| 31 Dec 19 | 0 | -19 | 6 | 16 |
| 30 Sep 19 | 0 | -17 | 6 | 14 |
| 30 Jun 19 | 0 | -16 | 6 | 12 |
| 31 Mar 19 | 0 | -13 | 5 | 9 |
| 31 Dec 18 | 0 | -11 | 4 | 8 |
| 30 Sep 18 | 0 | -9 | 3 | 6 |
| 30 Jun 18 | 0 | -11 | 3 | 5 |
| 31 Mar 18 | 0 | -10 | 2 | 4 |
| 31 Dec 17 | 0 | -8 | 2 | 3 |
| 30 Sep 17 | 0 | -7 | 1 | 3 |
| 30 Jun 17 | 0 | -2 | 1 | 1 |
Kaliteli Kazançlar: KRYS yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: KRYS 'nin mevcut net kar marjları (52.6%) geçen yılın (30.7%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: KRYS son 5 yılda karlı hale geldi ve kazançlarını yıllık 58.8% oranında artırdı.
Büyüme Hızlandırma: KRYS 'un son bir yıldaki kazanç büyümesi ( 129.7% ) 5 yıllık ortalamasını (yıllık 58.8% ) aşıyor.
Kazançlar vs. Sektör: KRYS geçen yılki kazanç büyümesi ( 129.7% ) Biotechs sektörünün 40.2% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: KRYS 'nin Özsermaye Getirisi ( 16.8% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/02 05:33 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Krystal Biotech, Inc. 21 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Caroline Palomeque | Berenberg |
| Alec Stranahan | BofA Global Research |
| Justin Zelin | B. Riley Securities, Inc. |